Cited by 896Fatty Acid Research and HealthSchizophrenia research and treatmentBipolar Disorder and Treatment

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial

Open access

Amminger, G. Paul, Schäfer, Miriam R., Papageorgiou, Konstantinos, Klier, Claudia M., Cotton, Sue M., Harrigan, Susan M., Mackinnon, Andrew, McGorry, Patrick D., Berger, Gregor E.·2010·Archives of General Psychiatry

DOI 10.1001/archgenpsychiatry.2009.192

Open this paper in CoChat — free account Open PDF

Abstract

CONTEXT: The use of antipsychotic medication for the prevention of psychotic disorders is controversial. Long-chain omega-3 (omega-3) polyunsaturated fatty acids (PUFAs) may be beneficial in a range of psychiatric conditions, including schizophrenia. Given that omega-3 PUFAs are generally beneficial to health and without clinically relevant adverse effects, their preventive use in psychosis merits investigation. OBJECTIVE: To determine whether omega-3 PUFAs reduce the rate of progression to first-episode psychotic disorder in adolescents and young adults aged 13 to 25 years with subthreshold psychosis. DESIGN: Randomized, double-blind, placebo-controlled trial conducted between 2004 and 2007. SETTING: Psychosis detection unit of a large public hospital in Vienna, Austria. PARTICIPANTS: Eighty-one individuals at ultra-high risk of psychotic disorder. INTERVENTIONS: A 12-week intervention period of 1.2-g/d omega-3 PUFA or placebo was followed by a 40-week monitoring period; the total study period was 12 months. MAIN OUTCOME MEASURES: The primary outcome measure was transition to psychotic disorder. Secondary outcomes included symptomatic and functional changes. The ratio of omega-6 to omega-3 fatty acids in erythrocytes was used to index pretreatment vs posttreatment fatty acid composition. RESULTS: Seventy-six of 81 participants (93.8%) completed the intervention. By study's end (12 months), 2 of 41 individuals (4.9%) in the omega-3 group and 11 of 40 (27.5%) in the placebo group had transitioned to psychotic disorder (P = .007). The difference between the groups in the cumulative risk of progression to full-threshold psychosis was 22.6% (95% confidence interval, 4.8-40.4). omega-3 Polyunsaturated fatty acids also significantly reduced positive symptoms (P = .01), negative symptoms (P = .02), and general symptoms (P = .01) and improved functioning (P = .002) compared with placebo. The incidence of adverse effects did not differ between the treatment groups. CONCLUSIONS: Long-chain omega-3 PUFAs reduce the risk of progression to psychotic disorder and may offer a safe and efficacious strategy for indicated prevention in young people with subthreshold psychotic states. Trial Registration clinicaltrials.gov Identifier: NCT00396643.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/archgenpsychiatry.2009.192

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder
van Os, J., Linscott, R. J., Myin-Germeys, I., Delespaul, P., & Krabbendam, L. (2009) · Psychological Medicine · doi:10.1017/s0033291708003814 · Cited by 2,343
Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits
Mozaffarian, D., & Rimm, E. B. (2006) · JAMA · doi:10.1001/jama.296.15.1885 · Cited by 1,966
The Family History Method Using Diagnostic Criteria
Andreasen, N. C. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770220111013 · Cited by 1,903
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
Marshall, M., Lewis, S. W., Lockwood, A., Drake, R., Jones, P. B., & Croudace, T. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,595

Show all 45 references

Research works printed but not linked: 1

First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.

Sorted by citations

Items 401–500 of 895

Adult Medication-Free Schizophrenic Patients Exhibit Long-Chain Omega-3 Fatty Acid Deficiency: Implications for Cardiovascular Disease Risk
McNamara, R. K., Jandacek, R. J., Rider, T., Tso, P., Dwivedi, Y., & Pandey, G. N. (2013) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2013/796462 · Cited by 24
Assessing depression in youth at clinical high risk for psychosis: A comparison of three measures
DeVylder, J., Yang, L. H., Harkavy‐Friedman, J., Azimov, N., Walder, D. J., & Corcoran, C. M. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.002 · Cited by 25
Food Insecurity as a Social Determinant of Mental Health
Compton, M. T. (2014) · Psychiatric Annals · doi:10.3928/00485713-20140108-08 · Cited by 28
Astaxanthin and Docosahexaenoic Acid Reverse the Toxicity of the Maxi-K (BK) Channel Antagonist Mycotoxin Penitrem A
Goda, A. A., Naguib, K., Mohamed, M. M., Amra, H., Nada, S. A., Abdel-Ghaffar, A.-R., Gissendanner, C. R., & Sayed, K. A. E. (2016) · Marine Drugs · doi:10.3390/md14110208 · Cited by 24
Genetic advances, biochemical and clinical features and critical approach to treatment of patients with X-linked hypophosphatemic rickets.
Baroncelli, G. I., Bertelloni, S., Sodini, F., Galli, L., Vanacore, T., Fiore, L., & Saggese, G. (2004) · PubMed · Cited by 24
Prediction and prevention of psychosis: current progress and future tasks
Ruhrmann, S., Schultze‐Lutter, F., Schmidt, S. J., Kaiser, N., & Klosterkötter, J. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0541-5 · Cited by 23
Young people at risk of psychosis: Their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial
Byrne, R. E., & Morrison, A. P. (2014) · Psychology and Psychotherapy: Theory, Research and Practice · doi:10.1111/papt.12013 · Cited by 23
Omega-3 supplementation reduces aggressive behavior: A meta-analytic review of randomized controlled trials
Raine, A., & Brodrick, L. (2024) · Aggression and Violent Behavior · doi:10.1016/j.avb.2024.101956 · Cited by 23
Predicting the risk of psychosis onset: advances and prospects
Strobl, E. V., Eack, S. M., Swaminathan, V., & Visweswaran, S. (2012) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2012.00383.x · Cited by 22
Prevention: Before the break
Solis, M. (2014) · Nature · doi:10.1038/508s12a · Cited by 22
Identification of the Antidepressant Function of the Edible Mushroom Pleurotus eryngii
Park, Y. S., Jang, S., Lee, H., Kang, S. H., Seo, H., Yeon, S., Lee, D., & Yun, C. (2021) · Journal of Fungi · doi:10.3390/jof7030190 · Cited by 22
Omega-3 fatty acids during adolescence prevent schizophrenia-related behavioural deficits: Neurophysiological evidences from the prenatal viral infection with PolyI:C
Casquero‐Veiga, M., Romero‐Miguel, D., MacDowell, K. S., Torres-Sánchez, S., Garcia-Partida, J. A., Lamanna‐Rama, N., Gómez‐Rangel, V., Romero‐Miranda, A., Berrocoso, E., Leza, J. C., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.02.001 · Cited by 22
Prenatal and Childhood Immuno-Metabolic Risk Factors for Adult Depression and Psychosis
Kappelmann, N., Perry, B. I., & Khandaker, G. M. (2022) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000322 · Cited by 22
The association between polyunsaturated fatty acid consumption and the transition to psychosis in ultra-high risk individuals
Pawełczyk, T., Trafalska, E., Kotlicka‐Antczak, M., & Pawełczyk, A. M. (2016) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2016.03.010 · Cited by 22
Therapeutic Potential of Physical Exercise in Early Psychosis
Noordsy, D. L., Burgess, J. D., Hardy, K. V., Yudofsky, L. M., & Ballon, J. S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17060716 · Cited by 22
Advances in clinical staging, early intervention, and the prevention of psychosis
Gupta, T., & Mittal, V. A. (2019) · F1000Research · doi:10.12688/f1000research.20346.1 · Cited by 22
Has improved treatment contributed to the declining rate of transition to psychosis in ultra-high-risk cohorts?
Formica, M., Phillips, L., Hartmann, J., Yung, A. R., Wood, S. J., Lin, A. P., Amminger, G. P., McGorry, P. D., & Nelson, B. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.04.028 · Cited by 23
Self-citation
Nutraceuticals and probiotics in the management of psychiatric and neurological disorders: A focus on microbiota-gut-brain-immune axis
Tong, J., Satyanarayanan, S. K., & Su, H. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.08.027 · Cited by 24
Prevention of the First Episode of Psychosis
McFarlane, W. R. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2010.11.012 · Cited by 22
Youth depression alleviation: the Fish Oil Youth Depression Study ( YoDA ‐F): A randomized, double‐blind, placebo‐controlled treatment trial
Rice, S., Hickie, I. B., Yung, A. R., Mackinnon, A. J., Berk, M., Davey, C. G., Hermens, D. F., Hetrick, S. E., Parker, A. G., Schäfer, M. R., et al. (2014) · Early Intervention in Psychiatry · doi:10.1111/eip.12166 · Cited by 24
Self-citation
A Classification of Sociomedical Health Indicators: Perspectives for Health Administrators and Health Planners
Siegmann, A. E. (1976) · International Journal of Health Services · doi:10.2190/my7u-4bgm-9qfy-n0tn · Cited by 22
Identifying and Treating the Prodromal Phases of Bipolar Disorder and Schizophrenia
Conroy, S. K., Francis, M., & Hulvershorn, L. A. (2018) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-018-0138-0 · Cited by 21
Boundary lipids of the nicotinic acetylcholine receptor: Spontaneous partitioning via coarse-grained molecular dynamics simulation
Sharp, L., Salari, R., & Brannigan, G. H. (2019) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2019.01.005 · Cited by 22
Pharmacotherapy and clinical characteristics of ultra‐high‐risk for psychosis according to conversion status: a naturalistic observational study
Kim, E., Jang, J. H., Park, H., Shim, G., Hwang, J. Y., Kim, S. N., & Kwon, J. S. (2011) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2011.00295.x · Cited by 21
Present and future of developmental neuropsychopharmacology
Arango, C. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.11.003 · Cited by 22
If waking and dreaming consciousness became de-differentiated, would schizophrenia result?
Llewellyn, S. (2011) · Consciousness and Cognition · doi:10.1016/j.concog.2011.03.022 · Cited by 21
Broad-Spectrum Micronutrient Treatment for Attention-Deficit/Hyperactivity Disorder: Rationale and Evidence to Date
Rucklidge, J. J., & Kaplan, B. J. (2014) · CNS Drugs · doi:10.1007/s40263-014-0190-2 · Cited by 21
Reduction in Incidence of Hospitalizations for Psychotic Episodes Through Early Identification and Intervention
McFarlane, W. R., Susser, E., McCleary, R., Verdi, M., Lynch, S., Williams, D. S., & McKeague, I. W. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300336 · Cited by 21
At-risk mental state for psychosis: identification and current treatment approaches
Thompson, A. D., Marwaha, S., & Broome, M. R. (2016) · BJPsych Advances · doi:10.1192/apt.bp.115.015487 · Cited by 21
Adjunctive low-dose docosahexaenoic acid (DHA) for major depression: An open-label pilot trial
Smith, D. J., Sarris, J. J., Dowling, N. L., O’Connor, M., & Ng, C. H. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1283128 · Cited by 21
Popular Herbal and Natural Remedies Used in Psychiatry
Mischoulon, D. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20170041 · Cited by 23
Evidence-based psychotherapy for the prevention and treatment of first-episode psychosis
Müller, H., Laier, S., & Bechdolf, A. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0538-0 · Cited by 20
Intervention in at-risk states for developing psychosis
Ruhrmann, S., Schultze‐Lutter, F., Bechdolf, A., & Klosterkötter, J. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-010-0139-5 · Cited by 20
Emerging drugs for schizophrenia
Biedermann, F., & Fleischhacker, W. W. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.556112 · Cited by 20
Omega-3 fatty acid deficiency disrupts endocytosis, neuritogenesis, and mitochondrial protein pathways in the mouse hippocampus
English, J. A., Harauma, A., Föcking, M., Wynne, K. J., Scaife, C., Cagney, G., Moriguchi, T., & Cotter, D. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00208 · Cited by 20
The Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 23
Transition to psychosis in randomized clinical trials of individuals at clinical high risk of psychosis compared to observational cohorts: a systematic review and meta-analysis
de Pablo, G. S., Davies, C., Ruiz, H. D. D., Solmi, M., Shin, J. I., Carvalho, A. F., Raduà, J., & Fusar‐Poli, P. (2021) · European Psychiatry · doi:10.1192/j.eurpsy.2021.2222 · Cited by 20
Differences in omega‐3 and omega‐6 polyunsaturated fatty acid consumption in people at ultra‐high risk of psychosis, first‐episode schizophrenia, and in healthy controls
Pawełczyk, T., Trafalska, E., Pawełczyk, A. M., & Kotlicka‐Antczak, M. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12267 · Cited by 20
Aripiprazole for Drug-Naive or Antipsychotic-Short-Exposure Subjects With Ultra-High Risk State and First-Episode Psychosis
Liu, C., Chien, Y., Hsieh, M. H., Hwang, T., Hwu, H., & Liu, C. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31827cb017 · Cited by 20
Neurodegenerative disorders share common features of “loss of function” states of a proposed mechanism of nervous system functions
Vadakkan, K. I. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.06.042 · Cited by 21
Prader-Willi syndrome mental health research strategy workshop proceedings: the state of the science and future directions
Schwartz, L., Holland, A. J., Dykens, E. M., Strong, T. V., Roof, E., & Bohonowych, J. E. S. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0504-1 · Cited by 20
Novel biotherapies are needed in youth mental health
Amminger, G. P., Berger, M., Rice, S., Davey, C. G., Schäfer, M. R., & McGorry, P. D. (2017) · Australasian Psychiatry · doi:10.1177/1039856217698237 · Cited by 21
Self-citation
Discrimination of isobaric and isomeric lipids in complex mixtures by combining ultra-high pressure liquid chromatography with collision and ozone-induced dissociation
Batarseh, A. M., Abbott, S. K., Duchoslav, E., Alqarni, A., Blanksby, S. J., & Mitchell, T. W. (2018) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2018.05.016 · Cited by 20
Evaluation of variability in individual response to treatments in the clinical high-risk state for psychosis: A meta-analysis
Raduà, J., Davies, C., & Fusar‐Poli, P. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.05.010 · Cited by 20
A review of the biologic and pharmacologic role of docosapentaenoic acid n-3
Yazdi, P. G. (2014) · F1000Research · doi:10.12688/f1000research.2-256.v2 · Cited by 21
Personalized Medicine of Omega-3 Fatty Acids in Depression Treatment in Obese and Metabolically Dysregulated Patients
Wu, S., Chen, W.-J., Chang, J. P., Guu, T., Hsin, M.-C., Huang, C., Mischoulon, D., Capuron, L., & Su, K. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13061003 · Cited by 19
Marine omega‐3 fatty acids and mood disorders – linking the sea and the soul
Hegarty, B. D., & Parker, G. B. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01703.x · Cited by 21
Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: Analysis of the EDIE-2 trial
Flach, C., French, P., Dunn, G., Fowler, D. G., Gumley, A. I., Birchwood, M. J., Stewart, S., & Morrison, A. P. (2015) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.114.153320 · Cited by 19
Psychosis prediction and clinical utility in familial high‐risk studies: selective review, synthesis, and implications for early detection and intervention
Shah, J. L., Tandon, N., & Keshavan, M. S. (2013) · Early Intervention in Psychiatry · doi:10.1111/eip.12054 · Cited by 19
Fish oil as a management component for mood disorders – an evolving signal
Hegarty, B. D., & Parker, G. B. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835ab4a7 · Cited by 19
Young people at ultra high risk for psychosis: research from the PACE clinic
Yung, A. R., & Nelson, B. (2011) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462011000600003 · Cited by 20
A supplementary circuit rule-set for the neuronal wiring
Vadakkan, K. I. (2013) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2013.00170 · Cited by 20
Pharmacological anti-inflammatory treatment in children and adolescents with depressive symptoms: A systematic-review and meta-analysis
Vöckel, J., Markser, A. M., Wege, L., Wunram, H. L., Sigrist, C., & Koenig, J. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.09.006 · Cited by 19
Pro-inflammatory Cytokines in Psychiatric Disorders in Children and Adolescents: A Review
Miłkowska, P., Popko, K., Demkow, U. A., & Wolańczyk, T. (2017) · Advances in experimental medicine and biology · doi:10.1007/5584_2017_32 · Cited by 18
No effect of oral l-tryptophan or alpha-lactalbumin on total tryptophan levels in breast milk
Dowlati, Y., Ravindran, A. V., Maheux, M., Steiner, M. S., Stewart, D. E., & Meyer, J. H. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.03.005 · Cited by 18
A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study
Qurashi, I., Chaudhry, I. B., Khoso, A. B., Husain, M. O., Hafeez, D., Kiran, T., Lane, S., Naqvi, H., Minhas, F. A., Nizami, A. T., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.10.025 · Cited by 17
Alterations in levels and ratios of n–3 and n–6 polyunsaturated fatty acids in the temporal cortex and liver of vervet monkeys from birth to early adulthood
Miller, L. R., Jorgensen, M. J., Kaplan, J. R., Seeds, M. C., Rahbar, E., Morgan, T. M., Welborn, A., Chilton, S. M., Gillis, J., Hester, A. G., et al. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.12.009 · Cited by 17
Effects of omega-3 supplementation on interleukin and neurotrophin levels in an animal model of schizophrenia
Zugno, A. I., Canever, L., Mastella, G. A., Heylmann, A. S., Oliveira, M. B., Steckert, A. V., de Castro, A. A., Dal‐Pizzol, F., Quevedo, J., & Gama, C. S. (2015) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201520140714 · Cited by 19
Ethical Implications of the Mild Encephalitis Hypothesis of Schizophrenia
Riedmüller, R., & Müller, S. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00038 · Cited by 17
Vulnerability to omega-3 deprivation in a mouse model of NMDA receptor hypofunction
Islam, R., Trépanier, M., Milenkovic, M., Horsfall, W., Salahpour, A., Bazinet, R. P., & Ramsey, A. J. (2017) · Schizophrenia · doi:10.1038/s41537-017-0014-8 · Cited by 17
No Impact of Omega-3 Fatty Acid Supplementation on Symptoms or Hostility Among Patients With Schizophrenia
Qiao, Y., Liu, C. P., Han, H., Liu, F. J., Shao, Y., & Xie, B. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00312 · Cited by 17
Functional interactions between cannabinoids, omega‐3 fatty acids, and peroxisome proliferator‐activated receptors: Implications for mental health pharmacotherapies
Jung, T., Hudson, R., Rushlow, W. J., & Laviolette, S. R. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.15023 · Cited by 17
State marker properties of niacin skin sensitivity in ultra-high risk groups for psychosis - An optical reflection spectroscopy study
Langbein, K., Schmidt, U., Schack, S., Biesel, N. J., Rudzok, M., Amminger, G. P., Berger, M., Sauer, H., & Smesny, S. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.06.007 · Cited by 17
Self-citation
DSM‐5 and the ‘Psychosis Risk Syndrome’: The DSM‐5 proposal is better than DSM‐IV
Woods, S. W., Carlson, J., & McGlashan, T. H. (2010) · Psychosis · doi:10.1080/17522439.2010.511719 · Cited by 17
Food-Intake Normalization of Dysregulated Fatty Acids in Women with Anorexia Nervosa
Nguyen, N., Dow, M. T., Woodside, D. B., German, J. B., Quehenberger, O., & Shih, P.-A. B. (2019) · Nutrients · doi:10.3390/nu11092208 · Cited by 16
Favorable effects of omega-3 polyunsaturated fatty acids in attentional control and conversion rate to psychosis in 22q11.2 deletion syndrome
Armando, M., Ciampoli, M., Padula, M. C., Amminger, G. P., Crescenzo, F. D., Maeder, J., Schneider, M., Schaer, M., Managò, F., Eliez, S., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107995 · Cited by 17
Self-citation
Antipsychotic treatment of UHR (‘prodromal’) individuals
Yung, A. R. (2010) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2010.00191.x · Cited by 16
Omega-3 Supplementation for Psychotic Mania and Comorbid Anxiety in Children
Vesco, A. T., Lehmann, J., Gracious, B., Arnold, L. E., Young, A. S., & Fristad, M. A. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0141 · Cited by 17
Psychosis risk syndrome comorbid with panic attack disorder in a cannabis-abusing patient affected by Arnold–Chiari malformation type I
CASALE, A. D., Serata, D., Rapinesi, C., Simonetti, A., Tamorri, S. M., Comparelli, A., Carolis, A. D., Savoja, V., Kotzalidis, G. D., Sani, G., et al. (2012) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2011.12.008 · Cited by 16
The Treatment of Adolescents With Schizotypal Personality Disorder and Related Conditions: A Practice-Oriented Review of the Literature
Ryan, A. T., MacDonald, A. N., & Walker, E. F. (2013) · Clinical Psychology Science and Practice · doi:10.1037/h0101721 · Cited by 16
Interventions for Youth at High Risk for Bipolar Disorder and Schizophrenia
McNamara, R. K., Strawn, J. R., Chang, K., & DelBello, M. P. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.07.009 · Cited by 16
Assessment and treatment of individuals at high risk for psychosis
Andreou, C., Bailey, B. K., & Borgwardt, S. (2019) · BJPsych Advances · doi:10.1192/bja.2019.3 · Cited by 15
Toward an interdisciplinary science of adolescence: Insights from schizophrenia research
Kasai, K. (2012) · Neuroscience Research · doi:10.1016/j.neures.2012.12.001 · Cited by 16
A review of the biologic and pharmacological role of docosapentaenoic acid
Yazdi, P. G. (2013) · F1000Research · doi:10.12688/f1000research.2-256.v1 · Cited by 17
Mechanisms of Involvement of Eicosanoids and their Precursors in the Pathophysiology and Treatment of Schizophrenia
Schmidt, L., Ceglarek, U., Kortz, L., Hoop, M., Kirkby, K. C., Thiery, J., & Himmerich, H. (2013) · Medicinal Chemistry · doi:10.2174/1573406411309060002 · Cited by 16
Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis
Alqarni, A., Mitchell, T. W., McGorry, P. D., Nelson, B., Markulev, C., Yuen, H. P., Schäfer, M. R., Berger, M., Mossaheb, N., Schlögelhofer, M., et al. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.08.033 · Cited by 15
Self-citation
Prävention psychotischer Störungen
Klosterkötter, J. (2013) · Der Nervenarzt · doi:10.1007/s00115-013-3831-7 · Cited by 15
N-3 polyunsaturated fatty acids in psychiatric diseases: mechanisms and clinical data.
Zeman, M., Jirák, R., Vecka, M., Raboch, J., & Žák, A. (2012) · PubMed · Cited by 15
The Deletion of GPR40/FFAR1 Signaling Damages Maternal Care and Emotional Function in Female Mice
Aizawa, F., Ogaki, Y., Kyoya, N., Nishinaka, T., Nakamoto, K., Kurihara, T., Hirasawa, A., Miyata, A., & Tokuyama, S. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00082 · Cited by 15
Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate
Behdani, F., Roudbaraki, S. N., Saberi‐Karimian, M., Tayefi, M., Hebrani, P., Akhavanrezayat, A., Vahabi‐Amlashi, S., Ferns, G. A., & Ghayour‐Mobarhan, M. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.12.028 · Cited by 15
Omega‐3 fatty acids and neurocognitive ability in young people at ultra‐high risk for psychosis
McLaverty, A., Allott, K., Berger, M., Hester, R., McGorry, P. D., Nelson, B., Markulev, C., Yuen, H. P., Schäfer, M. R., Mossaheb, N., et al. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.13025 · Cited by 16
Self-citation
Cannabidiol for at risk for psychosis youth: A randomized controlled trial
Amminger, G. P., Lin, A. P., Kerr, M., Weller, A., Spark, J., Pugh, C., O’Callaghan, S., Berger, M., Clark, S. R., Scott, J. G., et al. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13182 · Cited by 17
Self-citation
Omega-3 fatty acid deficiency: A preventable risk factor for schizophrenia?
McNamara, R. K. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.12.017 · Cited by 15
Development of a Boston Treatment Program for Youth at Clinical High Risk for Psychosis: Center for Early Detection, Assessment, and Response to Risk (CEDAR)
Friedman‐Yakoobian, M. S., West, M. L., Woodberry, K. A., O’Donovan, K., Zimmet, S. V., Gnong-Granato, A., Giuliano, A. J., Guyer, M. E., Rodenhiser, J., Keshavan, M. S., et al. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000181 · Cited by 15
Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study
Parker, S., Mulligan, L. D., Milner, P., Bowe, S. E., & Palmier‐Claus, J. E. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.02741 · Cited by 14
Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: A randomized clinical trial
Szeszko, P. R., McNamara, R. K., Gallego, J. A., Malhotra, A. K., Govindarajulu, U. S., Peters, B. D., & Robinson, D. G. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.11.050 · Cited by 14
Natural compounds mitigate mycotoxins-induced neurotoxicity by modulating oxidative tonus: in vitro and in vivo insights – a review
Fabbro, L. D., Sari, M. H. M., Ferreira, L. M., & Furian, A. F. (2024) · Food Additives & Contaminants Part A · doi:10.1080/19440049.2024.2316750 · Cited by 14
Targeting the Immune System With Pharmacotherapy in Schizophrenia
Melbourne, J. K., Feiner, B., Rosen, C., & Sharma, R. P. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0114-0 · Cited by 14
Psychosis risk individuals show poor fitness and discrepancies with objective and subjective measures
Damme, K. S. F., Sloan, R. P., Bartels, M. N., Ozsan, A., Ospina, L. H., Kimhy, D., & Mittal, V. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-89301-5 · Cited by 15
Early Detection and Prevention of Schizophrenic Psychosis—A Review
Westhoff, M. S., Ladwig, J., Heck, J., Schülke, R., Groh, A., Deest, M., Bleich, S., Frieling, H., & Jahn, K. (2021) · Brain Sciences · doi:10.3390/brainsci12010011 · Cited by 14
The Use of Omega-3 Fatty Acids in Mental Illness
Gören, J. L., & Tewksbury, A. (2011) · Journal of Pharmacy Practice · doi:10.1177/0897190011422876 · Cited by 14
Aetiology of Schizophrenia and Implications for Nursing Practice: A Literature Review
Cunningham, C., & Peters, K. (2014) · Issues in Mental Health Nursing · doi:10.3109/01612840.2014.908441 · Cited by 15
Relationship between amygdala volume and emotion recognition in adolescents at ultra-high risk for psychosis
Bartholomeusz, C. F., Whittle, S., Pilioussis, E., Allott, K., Rice, S., Schäfer, M. R., Pantelis, C., & Amminger, G. P. (2014) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2014.10.005 · Cited by 14
Self-citation
Emerging Treatments in Schizophrenia
Brown, H. E., & Roffman, J. L. (2016) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000101 · Cited by 14
Medical nutrition in mental health and disorders
Raju, M. S. V. K. (2017) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_193_17 · Cited by 14
Sex influences in the preventive effects of peripubertal supplementation with N-3 polyunsaturated fatty acids in mice exposed to the two-hit model of schizophrenia
da Costa, A. E. M., Gomes, N. S., Filho, C. V. J. G., Linhares, M. G. O. E. S., da Costa, R. O., Filho, A. J. M. C., Cordeiro, R. C., Vasconcelos, G. S., da Silva, F. E. R., Araújo, T. D. S., et al. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173949 · Cited by 14
Managing the Prodrome of Schizophrenia
Fleischhacker, W. W., & Simma, A. M. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_5 · Cited by 14
Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
Susai, S. R., Healy, C., Mongan, D., Heurich, M., Byrne, J. F., Cannon, M. D., Cagney, G., Wynne, K. J., Markulev, C., Schäfer, M. R., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02217-0 · Cited by 13
Self-citation
Omega-3 supplements in the prevention and treatment of youth depression and anxiety symptoms: A scoping review
Reily, N. M., Tang, S., Negrone, A., Gan, D. Z. Q., Sheanoda, V., & Christensen, H. M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284057 · Cited by 17
Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3 polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary results from a randomized controlled trial
Giollabhui, N. M., Mischoulon, D., Dunlop, B. W., Kinkead, B. L., Schettler, P. J., Liu, R. T., Okereke, O. I., Lamon‐Fava, S., D, M. F. M., & Rapaport, M. H. (2023) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2023.100666 · Cited by 14

Authors: Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E.
Affiliations: Medical University of Vienna (AT)
The University of Melbourne (AU)
Clienia AG (CH)
ORCID: Amminger, G. Paul
Papageorgiou, Konstantinos
Klier, Claudia M.
Cotton, Sue M.
Mackinnon, Andrew
McGorry, Patrick D.
Berger, Gregor E.
Venue: Archives of General Psychiatry
Publisher: American Medical Association (AMA)
Published: 2010-02-01
Volume: 67
Issue: 2
Pages: 146
ISSN: 0003-990X (ISSN-L)
DOI: 10.1001/archgenpsychiatry.2009.192
OpenAlex: W2130372506
Cited by: 896
References: 45
Citations by year: 2026: 13 · 2025: 20 · 2024: 29 · 2023: 22 · 2022: 20 · 2021: 51 · 2020: 42 · 2019: 59 · 2018: 33 · 2017: 52 · 2016: 69 · 2015: 82 · 2014: 95 · 2013: 85 · 2012: 98
FWCI: 92.57
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Archives of General Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: Stanley Medical Research Institute (03T-315)
Topics: Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords: omega-3 polyunsaturated fatty acids, clinical high risk for psychosis, schizophrenia, adolescents and young adults, n-6/n-3 ratio, erythrocyte fatty acids, positive symptoms, negative symptoms, functional outcome, dietary supplementation, psychosis prevention, omega-3 deficiency
MeSH terms: Adolescent, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Female, Health Status, Humans, Male, Patient Acceptance of Health Care, Psychotic Disorders, Risk Factors, Schizotypal Personality Disorder, Severity of Illness Index, Fatty Acids, Omega-3, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks